Please assess the completion status of the following clinical trial:

Trial Title: IGF-1 and Bone Loss in Women With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45 years~* AN defined by DSM-IV diagnostic criteria, including weight less than 85% of ideal body weight (restricting or binge/purge type, BMI 15-17.5) OR meet criteria for sub-threshold AN, i.e., all DSM-IV criteria except that patients can have a BMI of \<18.5 kg/m2 with or without amenorrhea~* Oral contraceptive use prior to enrollment~* BMD T score \< -1.0~* Normal FSH and TSH or free T4~* Normal serum 25-OH vitamin D (\>20 ng/mL) and calcium levels~* Ongoing care from a primary care provider~* Agree to use barrier contraception~Exclusion Criteria:~* Any subject with contraindications to risedronate~* Any subject with binge-purge subtype of anorexia nervosa who vomits regularly as their form of purging (vs. those who use laxatives or diuretics) and who have significant periodontal disease, tooth erosion or an invasive dental or periodontal procedure within the previous three months.~* Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure~* Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives. Bisphosphonates must have been discontinued for at least one year before participation~* Serum potassium \<3.0 meq/L~* Serum ALT \>3 times upper limit of normal~* eGFR of less than 30 ml/min~* Pregnant and/or breastfeeding~* Diabetes mellitus~* Active substance abuse, including alcohol~* History of malignancy~* Atraumatic fracture within the prior year

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- rhIGF-1 followed by Risedronate (Type: ACTIVE_COMPARATOR): Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
- Risedronate (Type: ACTIVE_COMPARATOR): Risedronate 35mg PO once weekly for 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).